In an illustration of how techniques for studying the proteome are finding an increasingly wide array of potential applications in drug discovery, AstraZeneca last week agreed to work with Ambit Biosciences to use the company’s phage display and affinity chromatography technology to identify proteins that interact with specific small molecules.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.